Pancreatic Cancer Research

ResearcherNantong UniversityNo recent work listed

Yuan‐Lin Zheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1754-0508; OpenAlex author ID A5100630484. Sources: OpenAlex.

Their work

Papers
4 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper

Papers 4

  1. Co-delivery of gemcitabine and Triapine by calcium carbonate nanoparticles against chemoresistant pancreatic cancer. First author DOI 10.1016/j.ijpharm.2023.122844↗
  2. Retraction Notice to: Bone Marrow Mesenchymal Stem Cell-Derived Exosomal MicroRNA-126-3p Inhibits Pancreatic Cancer Development by Targeting ADAM9. Last author DOI 10.1016/j.omtn.2022.08.024↗
  3. M1 Macrophage-Derived Exosomes Loaded with Gemcitabine and Deferasirox against Chemoresistant Pancreatic Cancer. First author DOI 10.3390/pharmaceutics13091493↗
  4. Bone Marrow Mesenchymal Stem Cell-Derived Exosomal MicroRNA-126-3p Inhibits Pancreatic Cancer Development by Targeting ADAM9. Last author DOI 10.1016/j.omtn.2019.02.022↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yongmei Zhao · 2 shared papers, 2021–2023 · strength 0.38
  2. Tianqing Liu · 2 shared papers, 2021–2023 · strength 0.38
  3. Yi Zhang · 1 shared paper, 2021 · strength 0.16
  4. Hongyan Zhu · 1 shared paper, 2021 · strength 0.16
  5. Dongmei Wu · 1 shared paper, 2022 · strength 0.13
  6. Dongmei Wu · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.